Abstract
Twenty-two children with immune thrombocytopenic purpura (ITP) with long-lasting thrombocytopenia, adversely affecting their quality of life, were treated with a reduced rituximab regimen in order to eliminate B cells producing anti-platelet antibody. A single dose of rituximab resulted in a response rate similar to that reported for cases in which 4 doses of rituximab were used.
MeSH terms
-
Adolescent
-
Antibodies, Monoclonal / administration & dosage*
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Murine-Derived
-
B-Lymphocytes / metabolism
-
Blood Platelets / chemistry
-
Blood Platelets / immunology*
-
Child
-
Child, Preschool
-
Female
-
Humans
-
Male
-
Purpura, Thrombocytopenic, Idiopathic / drug therapy*
-
Rituximab
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
Rituximab